There were 37 randomly assigned to Liraglutide & 18 on placebo (2:1); At 54 weeks, non-motor symptoms scale scores had improved by 6.6 points in the liraglutide group & worsened by 6.5 points in the placebo group; MDS-UPDRS III (change from baseline) = not significantly different
Secondary outcome analysis revealed a significant improvement in MDS-UPDRS II scores in the treatment group (-4.1 points, p=0.001 - curiously, self assessed motor scores were significantly better)
"At 54 weeks, NMSS scores had improved by 6.6 points in the liraglutide group and worsened by 6.5 points in the placebo group, a 13.1 point adjusted mean difference (p=0.07)."
" MDS-UPDRS part III and MDRS-2 score changes from baseline did not significantly differ between active and placebo. Secondary outcome analysis revealed a significant improvement in MDS-UPDRS part-II scores in the treatment group (-4.1 points, p=0.001)."
MDS-UPDRS part-II: Motor Aspects of Experiences of Daily Living (M-EDL). Maximum score 52.
"Injection site reactions and gastrointestinal symptoms were common AEs. Eleven serious AEs were reported, none of which related to the study intervention."
I do wonder what the serious adverse events were though.
In summary, myricetin was determined to be a small-molecule chemical agent that activates GLP-1R, and its physiochemical properties suggest that myricetin could be the first natural agonist of GLP-1R that can be orally administered.
" MDS-UPDRS part III and MDRS-2 score changes from baseline did not significantly differ between active and placebo. Secondary outcome analysis revealed a significant improvement in MDS-UPDRS part-II scores in the treatment group (-4.1 points, p=0.001)."
Can someone explain this to me please?
As I read it, the first part of the sentence says it didn’t make a difference to motor aspects of the disease. Then the second part says it did? What is secondary outcome analysis and why does that differ from the baseline scores?
"MDRS-2" is Mattis Dementia Rating Scale. MDS-UPDRS part II and MDS-UPDRS part III refer to different types of motor symptoms. Part II result was stat sig, whereas part III was not.
Baseline refers to beginning scores at the start of the trial, outcome refers to scores at the end of the trial.
Thanks. The cure Parkinson’s site says it is encouraging with regards to non motor symptoms and quality of life..
It was more the secondary outcome analysis I didn’t understand, but I read the clinical trials paper and get a better feel for it now. Promising results coming out of many trials now using GLP-1 agonists.
It's a very similar drug to exenatide which is phase 3. It's results further add to the theory that exenatide may slow or even stop the progression of parkinson at least in some people. It's a lot of ifs and maybes but it's very positive news.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
How many know that H2, hydrogen water has positive effects for those with Parkinsons? I didn't know.
Oral ANVS401 Improves Patients’ Motor Skills in Phase 2 Trial
Thumbs up for Nilotinib - Phase II Trials
